At AstraZeneca Switzerland, we are transforming the management of high-burden viral and bacterial threats. By pioneering innovative vaccines and targeted antibody therapies, our research tackles complex respiratory pathogens, addresses the critical challenge of antimicrobial resistance, and seeks lasting functional cures for chronic viral conditions.
Our focus areas
Viral Respiratory Diseases
Pathogens such as respiratory syncytial virus (RSV) place a heavy burden on healthcare systems. We focus on advanced immunizations and prophylactic treatments to reduce severe illness, prevent hospitalizations, and lower respiratory-related mortality.
For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch
References
- Maslova E, et al. 304. Global Incidence of Viral Lower Respiratory Tract Disease (LRTD) Episodes and Hospitalizations (2010-2021). Open Forum Infectious Diseases. 2025;12(Suppl 1):ofae631.094. Available at: https://doi.org/10.1093/ofid/ofae631.094 (accessed September 2026).
Veeva ID: CH-13773
Date of preparation: October 2026